MyoADR Technologies Corp. was founded by members of the lab to commercialize the intellectual property disclosed in patent application: “A Method for Predicting Increased Risk of Suffering Statin-induced Adverse Drug Reaction” (Application number: 13/540,598). SBIR proposals are currently being drafted to finance the startup operations.